Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
91. |
ECCT/23/04/02 | Shigella 53G study in Kenya Safety and feasibility of a Shigella sonnei 53G controlled human infection model in Kenyan adults: a dose finding and dose verification study |
Principal Investigator(s) 1. Melissa Kapulu 2. Fredrick Sawe Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
92. |
ECCT/23/05/02 | A5384 A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM) |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
View |
93. |
ECCT/23/03/06 | PDMC-II Dihydroartemisinin-piperaquine and azithromycin for the post-discharge management of children with severe anaemia in Malawi, Kenya and Uganda; A, multicentre, parallel-group, two-arm, randomised, double-blind superiority trial. |
Principal Investigator(s) 1. Simon Kariuki 2. Titus Kwambai Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital |
View |
94. |
ECCT/23/05/01 | A5356 A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary Tuberculosis |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya MOI UNIVERSITY CLINICAL RESEARCH CENTRE |
View |
95. |
ECCT/23/03/07 | PLATINUM STUDY (PLATINUM): A multi-part, multi-center PLATform study to assess the efficacy, safety, tolerability and pharmacokinetics of anti-malarial agents administered as monotherapy and/or combination therapy IN patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Godfrey (Site 5001) Allan Otieno 2. Bernhard Ragama Ogutu 3. John (Site 5002) Orimbo Site(s) in Kenya 1. KEMRI Kondele Children Hospital (Kisumu county) 2. AHERO CLINICAL TRIALS UNIT (Kisumu county) |
View |